Publications
2024
Balboni B., Marotta R., Rinaldi F., Milordini G., Varignani G., Girotto S., Cavalli A.
An integrative structural study of the human full-length RAD52 at 2.2 Å resolution
Communications Biology, vol. 7, (no. 1)
2024
Brindani N., Vuong L.M., La Serra M.A., Salvador N., Menichetti A., Acquistapace I.M., Ortega J.A., Veronesi M., Bertozzi S.M., Summa M., Girotto S., Bertorelli R., Armirotti A., Ganesan A.K., De Vivo M.
Discovery of CDC42 Inhibitors with a Favorable Pharmacokinetic Profile and Anticancer In Vivo Efficacy
Journal of Medicinal Chemistry, vol. 67, (no. 12), pp. 10401-10424
2024
Balboni B., Marotta R., Rinaldi F., Milordini G., Varignani G., Girotto S., Cavalli A.
Human full-length RAD52 at 2.2 Å resolution: an integrative structural biology study
Communications Biology
Article
Journal
2024
Rinaldi F., Girotto S.
Structure-based approaches in synthetic lethality strategies
Current Opinion in Structural Biology, vol. 88
2023
Myers S. H., Poppi L., Rinaldi F., Veronesi M., Ciamarone A., Previtali V., Bagnolini G., Schipani F., Ortega Martínez J. A., Girotto S., Di Stefano G., Farabegoli F., Walsh N., De Franco F., Roberti M., Cavalli A.
An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer
European Journal of Medicinal Chemistry
2023
Brindani N., Vuong L.M., Acquistapace I.M., La Serra M.A., Ortega J.A., Veronesi M., Bertozzi S.M., Summa M., Girotto S., Bertorelli R., Armirotti A., Ganesan A.K., De Vivo M.
Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer
Journal of Medicinal Chemistry, vol. 66, (no. 8), pp. 5981-6001
2023
Balboni B., Masi M., Rocchia W., Girotto S., Cavalli A.
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
International Journal of Molecular Sciences, vol. 24, (no. 8)
2023
Brusa I., Sondo E., Pesce E., Tomati V., Gioia D., Falchi F., Balboni B., Ortega Martinez J.A., Veronesi M., Romeo E., Margaroli N., Recanatini M., Girotto S., Pedemonte N., Roberti M., Cavalli A.
Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5
Journal of Medicinal Chemistry, vol. 66, (no. 14), pp. 9797-9822
2023
Rinaldi F., Schipani F., Balboni B., Catalano F., Marotta R., Myers S.H., Previtali V., Veronesi M., Scietti L., Cecatiello V., Pasqualato S., Ortega J.A., Girotto S., Cavalli A.
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
Angewandte Chemie - International Edition, vol. 62, (no. 51)
2023
Balboni B., Rinaldi F., Previtali V., Ciamarone A., Girotto S., Cavalli A.
Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies
Cancers, vol. 15, (no. 6)
2023
Balboni B., Marotta R., Rinaldi F., Girotto S., Cavalli A.
Novel structural insights on full-length human RAD52: Cryo-EM and beyond
bioRxiv
2023
Previtali V., Myers S.H., Poppi L., Wynne K., Casamassima I., Girotto S., Di Stefano G., Farabegoli F., Roberti M., Oliviero G., Cavalli A.
Preomic profile of BxPC-3 cells after treatment with BRC4
Journal of Proteomics, vol. 288
2022
Demuro S., Sauvey C., Tripathi S.K., Di Martino R.M.C., Shi D., Ortega J.A., Russo D., Balboni B., Giabbai B., Storici P., Girotto S., Abagyan R., Cavalli A.
ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
European Journal of Medicinal Chemistry, vol. 229
2022
Barbieri F., Bosio A.G., Pattarozzi A., Tonelli M., Bajetto A., Verduci I., Cianci F., Cannavale G., Palloni L.M.G., Francesconi V., Thellung S., Fiaschi P., Mazzetti S., Schenone S., Balboni B., Girotto S., Malatesta P., Daga A., Zona G., Mazzanti M., Florio T.
Chloride intracellular channel 1 activity is not required for glioblastoma development but its inhibition dictates glioma stem cell responsivity to novel biguanide derivatives
Journal of Experimental and Clinical Cancer Research, vol. 41, (no. 1)
2022
Balboni B., Tripathi S.K., Veronesi M., Russo D., Penna I., Giabbai B., Bandiera T., Storici P., Girotto S., Cavalli A.
Identification of Novel GSK-3β Hits Using Competitive Biophysical Assays
International Journal of Molecular Sciences, vol. 23, (no. 7)